Home › Funds › CAXTON CORP › LXEO

CAXTON CORP position in LXEO

LEXEO THERAPEUTICS INC COM · Health Care

CAXTON CORP reported holding 16,962 shares of LXEO (LEXEO THERAPEUTICS INC COM) in its Q2 2026 13F filing — a position valued at US$79K, representing 4.26% of its reported portfolio and ranking #7 among its reported holdings. CAXTON CORP has disclosed LXEO holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)16.96K sh
Reported value held$78.96K
Portfolio Weight4.26%
First reportedQ4 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How CAXTON CORP's LXEO position evolved

CAXTON CORP first disclosed a stake in LXEO in Q4 2023 at 10,319 shares (US$138K). The position peaked in Q2 2024 at 17,851 shares, worth US$286K. Across 11 filings, CAXTON CORP increased the stake 2 time(s), trimmed it 2 time(s) and left it unchanged 6 time(s). The most recent filing (Q2 2026) shows 16,962 shares valued at US$79K — an increase of 3,019 shares quarter over quarter.. Notable position changes include a 73% increase in Q2 2024 (shares fell 59% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 10.32K $138.48K New
Q1 2024 10.32K $161.80K Hold
Q2 2024 17.85K $286.33K Add
Q3 2024 17.85K $161.37K Hold
Q4 2024 17.85K $117.46K Hold
Q1 2025 17.85K $61.94K Hold
Q2 2025 17.33K $69.67K Reduce
Q3 2025 17.33K $115.08K Hold
Q4 2025 13.94K $138.45K Reduce
Q1 2026 13.94K $80.03K Hold
Q2 2026 16.96K $78.96K Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About LXEO and 13F data

LXEO (LEXEO THERAPEUTICS INC COM) is a Health Care company. 41 other funds we track also report a position in LXEO — the largest reported positions include MONTANOVA CAPITAL, LLC (US$29.7M), Affinity Asset Advisors, LLC (US$27.0M), Frazier Life Sciences Management, L.P. (US$22.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding LXEO

All LXEO fund holders →

FAQ

How long has CAXTON CORP held LXEO?

CAXTON CORP has disclosed LXEO holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is CAXTON CORP's current position in LXEO?

As of Q2 2026, CAXTON CORP holds 16.96K shares of LXEO (LEXEO THERAPEUTICS INC COM), valued at $78.96K, representing 4.26% of its reported portfolio and ranking #7.

Has CAXTON CORP been buying or selling LXEO?

In the latest 13F filing (Q2 2026), CAXTON CORP increased its position in LXEO. The position peaked in Q2 2024 at 17.85K shares.

Which other funds hold LXEO?

Other major institutional holders of LXEO include MONTANOVA CAPITAL, LLC, Affinity Asset Advisors, LLC, Frazier Life Sciences Management, L.P., among 41 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.